Skip to main content
Premium Trial:

Request an Annual Quote

Prenosis Nabs Up to $4.3 Million From US DoD to Develop Early Sepsis POC Test

NEW YORK ─ The US Department of Defense has awarded Prenosis up to $4.3 million for the development of its technology for the early detection of sepsis in warfighters at the point of care, the firm said Wednesday.

Prenosis, a University of Illinois at Urbana-Champaign spinout based in Chicago, is developing the Immunix Emergency Point-of-Care system for diagnostic testing.

The system uses the firm's Immunix platform which leverages machine learning algorithms and biological and clinical data to detect sepsis as early as possible in hospitals. The system also includes Prenosis' ImmunoScan point-of-care technology, wearable devices, and a central mobile app linked to its Nosis dataset, a biomarker-based clinical dataset for sepsis.

In a project funded by the DoD Defense Threat Reduction Agency, Prenosis will adapt the Immunix platform for detection of sepsis in warfighters. Prenosis said it will contract with St. Louis, Missouri-based Kypha, a developer of biomarker-based diagnostic tests to detect immune system activity, to develop hardware for the project. Prenosis has licensed Kypha's RapiPlex reader and multiplex cartridge technology platform to supply data for its algorithms.

"Our point-of-care solution has the potential to help provide accurate and early sepsis detection in warfighters at the frontlines, and could also improve pre-hospital sepsis identification in civilian communities," Bobby Reddy, Prenosis CEO and cofounder, said in a statement.

Last month, Prenosis announced it is expanding a partnership with Roche to accelerate and improve the detection of sepsis.